Q3 Revenue Falls 45% to $404K, Missing Estimates; Loss Per Share 53 Cents
FEMY is trading near its 52-week low of $1.255 (15% above the low) on light trading volume (0.1× avg).
Summary
Femasys posted Q3 revenue of $404,597, down 44.5% year over year, and missed the $619,500 analyst consensus by a wide margin. The adjusted loss came in at 53 cents per share versus the 52-cent consensus, with a net loss of $4.56 million. Management attributed the sales drop to international FemBloc order timing, so the shortfall looks like lumpy ordering rather than lost demand, but the top-line miss is still large relative to a company this size. This follows the 8-K filed minutes earlier with the same figures and comes after an August FDA approval for a modular PMA submission approach for FemBloc and a UNC Health partnership. The stock has lost 87.9% this year and 35.2% this quarter, and the $30M August private placement plus the pending $3.1 million lawsuit over its terms remain the key overhangs.
At the time of this announcement, FEMY was trading at $1.44 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.9M. The 52-week trading range was $1.26 to $20.80. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.